Two blood pressure drug combinations for people with heart disease after a stent
Compares two pairs of blood pressure medicines in people with high blood pressure after stenting.
Plain-language title generated from the registry record
Registry title: Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention
Key facts
- Where
- Moscow, RussiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT07683585, who can take part
Where in Russia
- National Medical Research Center for Therapy and Preventive MedicineMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Medical Research Center for Therapy and Preventive Medicine
- Trial code
- NCT07683585
- Record updated
- 6 July 2026
- Original description
This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting.Read full original descriptionShow less
Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention
This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting.
Patients requiring dual antihypertensive therapy will be randomized to receive either an angiotensin receptor blocker (ARB) combined with a thiazide diuretic or an ARB combined with a dihydropyridine calcium channel blocker.
The study will evaluate blood pressure control, angina symptoms, quality of life, need for treatment intensification, and healthcare utilization during follow-up. Clinical status will be assessed at discharge and during telemedicine follow-up visits at 2 weeks, 4 weeks, and 12 weeks after hospital discharge.
The primary endpoint is the percentage reduction in systolic and diastolic blood pressure. Secondary endpoints include frequency of angina episodes, exercise limitations, patient satisfaction with treatment, and medical consultations during follow-up.
The study is investigator-initiated and plans to enroll at least 207 participants.
Inclusion: Age 50 to 70 years; Arterial hypertension; Coronary artery disease; Hospitalization for elective percutaneous coronary intervention; Coronary artery stenting during the current hospitalization; Requirement for dual antihypertensive therapy; Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy; Ability and willingness to provide written informed consent.
Exclusion: Contraindications or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout; Acute coronary syndrome; Active malignancy; Chronic kidney disease stage 4-5; Type 2 diabetes mellitus; Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results; Heart failure with reduced ejection fraction; Women of reproductive age; Refusal or inability to provide informed consent; Pulmonary embolism; Permanent or persistent atrial fibrillation; Planned staged coronary stenting.